Lv6
2380 积分 2024-06-18 加入
The Affinity Advantage
11天前
已完结
Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors
15天前
已完结
Keratinocytes: new perspectives in inflammatory skin diseases
1个月前
已完结
Inhibitors supercharge kinase turnover through native proteolytic circuits
1个月前
已完结
Is Target-Based Drug Discovery Efficient? Discovery and “Off-Target” Mechanisms of All Drugs
1个月前
已完结
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
1个月前
已完结
Response and Resistance to RAS Inhibition in Cancer
1个月前
已完结
Navigating the Evolving Landscape of EGFR -Mutated NSCLC
2个月前
已完结
Cyclophilin A-Deficient Mice Are Resistant to Immunosuppression by Cyclosporine
2个月前
已完结
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
2个月前
已完结
皖公网安备34019202002308
